The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Novo Nordisk has appointed Mike Doustdar as its new CEO amid a challenging financial landscape. The company lowered its 2025 ...

(Reuters) -Novo Nordisk on Tuesday appointed insider Mike Doustdar as its new chief executive after the Danish obesity drug maker cut its full year outlook for the second time in 2025, sending its ...

Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief ...

Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo Nordisk has lowered its full-year 2025 sales and operating profit forecasts due to weaker-than-expected growth in its ...